Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, et al. - Given that higher‐risk Myelodysplastic syndromes (MDS) patients receiving therapy with 5‐azacytidine (AZA) are typically elderly with various comorbidities, however, there is a lack of clarity regarding the impact of comorbidities on the efficacy as well as safety of AZA in real‐world settings, so to address this topic, researchers studied data from 536 AZA‐managed patients having higher‐risk MDS, Myelodysplastic/Myeloproliferative neoplasms and low blast count Acute Myeloid Leukemia enrolled to the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes. Worse response and survival were independently predicted by an estimated glomerular filtration rate (eGFR) < 45 mL min−1/1.73 m², as demonstrated in the second largest real‐world series of MDS patients managed with AZA. The utility of this higher cut‐off, rather than often employed serum creatinine >2 mg/dL, was suggested as a more accurate marker of renal comorbidity during AZA treatment. Findings are also suggestive of the likely usefulness of the inclusion of eGFR in the prognostic evaluation of AZA‐treated MDS patients, both for routine practice and proper patient stratification in clinical trials with AZA combinations.